Click Here to return To Results

 

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011 See this aricle in Pubmed Article Abstract These findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing a combination of beneficial anti-inflammatory and possibly neuroprotective/reparative effects, may contribute to its efficacy in MS. In clinical trials, fingolimod was generally safe and well tolerated. Its interaction with S1PRs in a variety of tissues largely accounts for the reported adverse effects, which were seen more frequently with doses 2.5 to 10x the approved 0.5mg dose. Fingolimod�s unique mechanism of action distinguishes it from all other currently approved MS therapies.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction cerebral cortical atrophy complications disability,neurological efficacy fingolimod immunomodulation liver function enzymes MRI MRI,abnormal MRI,volumetry multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder vaccine

Click Here to return To Results